
Chardan Capital has decided to maintain its Buy rating of CRISPR Therapeutics (NASDAQ:CRSP) and lower its price target from $168.00 to $164.00.
Shares of CRISPR Therapeutics are trading down 8.24% over the last 24 hours, at $59.34 per share.

Chardan Capital has decided to maintain its Buy rating of CRISPR Therapeutics (NASDAQ:CRSP) and lower its price target from $168.00 to $164.00.
Shares of CRISPR Therapeutics are trading down 8.24% over the last 24 hours, at $59.34 per share.